RadioMedix, Inc. is a clinical stage biotechnology company based in Houston, Texas, specializing in the development of innovative targeted radiopharmaceuticals for the diagnosis, monitoring, and therapy of cancer. They offer a wide range of services, from drug discovery and pre-clinical investigations to manufacturing and analytical services, with a focus on PET imaging and therapeutic alpha and beta-labeled radiopharmaceuticals.
With their state-of-the-art facilities and expertise, RadioMedix is dedicated to changing the nuclear medicine landscape by providing precision and control in diagnosing and treating patients through their theranostic approach. They have also received significant funding and awards for their groundbreaking research and development in targeted alpha therapy.
Generated from the website